Amrubicin
- Generic Name
- Amrubicin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C25H25NO9
- CAS Number
- 110267-81-7
- Unique Ingredient Identifier
- 93N13LB4Z2
- Background
Amrubicin is a third-generation synthetic anthracycline currently in development for the treatment of small cell lung cancer. Pharmion licensed the rights to Amrubicin in November 2006. In 2002, Amrubicin was approved and launched for sale in Japan based on Phase 2 efficacy data in both SCLC and NSCLC. Since January 2005, Amrubicin has been marketed by Nippo...
- Indication
Investigated for use/treatment in lung cancer .
- Associated Conditions
- -
- Associated Therapies
- -
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-01-12
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 540
- Registration Number
- NCT06203210
- Locations
- 🇺🇸
Providence Medical Foundation, Fullerton, California, United States
🇺🇸David Geffen School of Medicine, Los Angeles, California, United States
🇺🇸Highlands Oncology Group, Springdale, Arkansas, United States
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-02-23
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Amgen
- Target Recruit Count
- 509
- Registration Number
- NCT05740566
- Locations
- 🇧🇪
Vitaz campus Sint-Niklaas Moerland, Sint-Niklaas, Belgium
🇧🇷Beneficencia Portuguesa de Sao Paulo - Bp, Sao Paulo, São Paulo, Brazil
🇦🇺Liverpool Hospital, Liverpool, New South Wales, Australia
Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer
- First Posted Date
- 2015-06-25
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 569
- Registration Number
- NCT02481830
- Locations
- 🇺🇸
Local Institution - 0024, New Haven, Connecticut, United States
🇺🇸Local Institution - 0173, Johnson City, New York, United States
🇧🇷Local Institution - 0093, Barretos, Sao Paulo, Brazil
A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies
- First Posted Date
- 2011-06-02
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Heather Wakelee
- Target Recruit Count
- 33
- Registration Number
- NCT01364727
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
🇺🇸Indiana University, Indianapolis, Indiana, United States
Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2011-05-18
- Last Posted Date
- 2018-09-18
- Lead Sponsor
- Michaela Liedtke
- Target Recruit Count
- 14
- Registration Number
- NCT01355705
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma
- First Posted Date
- 2011-04-08
- Last Posted Date
- 2018-04-23
- Lead Sponsor
- Matthew Galsky
- Target Recruit Count
- 22
- Registration Number
- NCT01331824
- Locations
- 🇺🇸
Indiana University Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
Amrubicin Chemotherapy as First Line in Metastatic or Unresectable Soft Tissue Sarcoma
- First Posted Date
- 2010-12-14
- Last Posted Date
- 2017-04-17
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 24
- Registration Number
- NCT01259375
- Locations
- 🇺🇸
Santa Monica, Santa Monica, California, United States
🇺🇸Huntsman Cancer Institute, Salt Lake City, Utah, United States
A Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-02-26
- Last Posted Date
- 2016-05-05
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 81
- Registration Number
- NCT01076504
- Locations
- 🇺🇸
Medical Oncology Associates of Augusta, Augusta, Georgia, United States
🇺🇸Northeast Arkansas Clinic, Jonesboro, Arkansas, United States
🇺🇸Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States
Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer
- First Posted Date
- 2009-12-16
- Last Posted Date
- 2022-05-03
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 78
- Registration Number
- NCT01033032
- Locations
- 🇺🇸
The Center for Cancer and Blood Disorders, Fort Worth, Texas, United States
🇺🇸Berks Hematology Oncology Associates, West Reading, Pennsylvania, United States
🇺🇸Center for Cancer and Blood Disorders, Bethesda, Maryland, United States
A Phase I Study to Assess the Safety, Pharmacokinetics, and Potential Effects of Amrubicin on the QT/QTc Interval in Cancer Patients With Advanced Solid Tumors.
- First Posted Date
- 2009-06-05
- Last Posted Date
- 2019-11-01
- Lead Sponsor
- Celgene
- Target Recruit Count
- 24
- Registration Number
- NCT00915083
- Locations
- 🇺🇸
James Graham Brown Cancer Center, Louisville, Kentucky, United States
🇺🇸Sarcoma Oncology Center, Santa Monica, California, United States
🇺🇸Sinai Hospital of Baltimore- Alvin and Lois Lapidus Cancer Institute, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.